High-dose glucocorticoids increase serum levels of soluble IL-6 receptor α and its ratio to soluble gp130: an additional mechanism for early increased bone resorption | Zendy

Andrea Dovio | Zendy; Laura Perazzolo | Zendy; L. Saba | Zendy; A Termine | Zendy; Marco Capobianco | Zendy; Antonio Bertolotto | Zendy; Alberto Angeli | Zendy

Open Access

High-dose glucocorticoids increase serum levels of soluble IL-6 receptor α and its ratio to soluble gp130: an additional mechanism for early increased bone resorption

Author(s) -

Andrea Dovio,

Laura Perazzolo,

L. Saba,

A Termine,

Marco Capobianco,

Antonio Bertolotto,

Alberto Angeli

Publication year - 2006

Publication title -

european journal of endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.897

H-Index - 148

eISSN - 1479-683X

pISSN - 0804-4643

DOI - 10.1530/eje.1.02147

Subject(s) - medicine , endocrinology , bone resorption , osteocalcin , glycoprotein 130 , receptor , bone remodeling , resorption , cytokine , osteoclast , n terminal telopeptide , interleukin 6 , chemistry , alkaline phosphatase , biochemistry , enzyme

Glucocorticoids (GCs) at pharmacological doses stimulate bone resorption. Mechanisms of this action are unclear. The osteoclastogenic cytokine interleukin (IL)-6 acts through an oligomeric receptor consisting of two subunits, gp80 (or IL-6 receptor alpha, IL-6Ralpha) and gp130; both exist in membrane and soluble forms. Soluble IL-6Ralpha (sIL-6Ralpha) enhances, while sgp130 inhibits IL-6 signalling. In vitro, GCs enhance many effects of IL-6 by up-regulation of IL-6Ralpha. The aim of the present study was to assess acute changes of IL-6 system in the peripheral blood of patients given high-dose GCs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research